Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
575 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cervical Cancer - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H1 2017, provides an overview of the Cervical Cancer (Oncology) pipeline landscape. Cervical cancer occurs when abnormal cells on the cervix grow out of control. Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Abnormal cervical cell changes rarely cause symptoms. Symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 32, 32, 47, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 2, 11 and 4 molecules, respectively. Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Cervical Cancer - Overview 7 Cervical Cancer - Therapeutics Development 8 Cervical Cancer - Therapeutics Assessment 28 Cervical Cancer - Companies Involved in Therapeutics Development 41 Cervical Cancer - Drug Profiles 86 Cervical Cancer - Dormant Projects 544 Cervical Cancer - Discontinued Products 548 Cervical Cancer - Product Development Milestones 549 Appendix 559
List of Tables
Number of Products under Development for Cervical Cancer, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Cervical Cancer - Pipeline by Abion Inc, H1 2017 Cervical Cancer - Pipeline by Abivax SA, H1 2017 Cervical Cancer - Pipeline by Admedus Ltd, H1 2017 Cervical Cancer - Pipeline by Advaxis Inc, H1 2017 Cervical Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017 Cervical Cancer - Pipeline by Agenus Inc, H1 2017 Cervical Cancer - Pipeline by AntiCancer Inc, H1 2017 Cervical Cancer - Pipeline by Antigen Express Inc, H1 2017 Cervical Cancer - Pipeline by Arbor Vita Corp, H1 2017 Cervical Cancer - Pipeline by ArQule Inc, H1 2017 Cervical Cancer - Pipeline by Asana BioSciences LLC, H1 2017 Cervical Cancer - Pipeline by AstraZeneca Plc, H1 2017 Cervical Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017 Cervical Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017 Cervical Cancer - Pipeline by BeiGene Ltd, H1 2017 Cervical Cancer - Pipeline by Bioleaders Corp, H1 2017 Cervical Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017 Cervical Cancer - Pipeline by Blirt SA, H1 2017 Cervical Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Cervical Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017 Cervical Cancer - Pipeline by Cancer Research Technology Ltd, H1 2017 Cervical Cancer - Pipeline by Cell Medica Ltd, H1 2017 Cervical Cancer - Pipeline by Cellceutix Corp, H1 2017 Cervical Cancer - Pipeline by Celleron Therapeutics Ltd, H1 2017 Cervical Cancer - Pipeline by Coherus BioSciences Inc, H1 2017 Cervical Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017 Cervical Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017 Cervical Cancer - Pipeline by CZ BioMed Corp, H1 2017 Cervical Cancer - Pipeline by DelMar Pharmaceuticals Inc, H1 2017 Cervical Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017 Cervical Cancer - Pipeline by Eisai Co Ltd, H1 2017 Cervical Cancer - Pipeline by Etubics Corp, H1 2017 Cervical Cancer - Pipeline by Eureka Therapeutics Inc, H1 2017 Cervical Cancer - Pipeline by EyeGene Inc, H1 2017 Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Cervical Cancer - Pipeline by Formune SL, H1 2017 Cervical Cancer - Pipeline by GamaMabs Pharma SA, H1 2017 Cervical Cancer - Pipeline by Gene Techno Science Co Ltd, H1 2017 Cervical Cancer - Pipeline by Genexine Inc, H1 2017 Cervical Cancer - Pipeline by Genmab A/S, H1 2017 Cervical Cancer - Pipeline by Genor BioPharma Co Ltd, H1 2017 Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017 Cervical Cancer - Pipeline by Glycostem Therapeutics BV, H1 2017 Cervical Cancer - Pipeline by Glycotope GmbH, H1 2017 Cervical Cancer - Pipeline by Gradalis Inc, H1 2017 Cervical Cancer - Pipeline by Immune Therapeutics Inc, H1 2017 Cervical Cancer - Pipeline by Immunomedics Inc, H1 2017 Cervical Cancer - Pipeline by Immunovaccine Inc, H1 2017 Cervical Cancer - Pipeline by Insys Therapeutics Inc, H1 2017 Cervical Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2017 Cervical Cancer - Pipeline by Johnson & Johnson, H1 2017 Cervical Cancer - Pipeline by Juno Therapeutics Inc, H1 2017 Cervical Cancer - Pipeline by Kaketsuken KK, H1 2017 Cervical Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017 Cervical Cancer - Pipeline by Kite Pharma Inc, H1 2017 Cervical Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017 Cervical Cancer - Pipeline by LondonPharma Ltd, H1 2017 Cervical Cancer - Pipeline by Mabion SA, H1 2017 Cervical Cancer - Pipeline by MedImmune LLC, H1 2017 Cervical Cancer - Pipeline by Merck & Co Inc, H1 2017 Cervical Cancer - Pipeline by Mycenax Biotech Inc, H1 2017 Cervical Cancer - Pipeline by Nanotherapeutics Inc, H1 2017 Cervical Cancer - Pipeline by Nektar Therapeutics, H1 2017 Cervical Cancer - Pipeline by NeoImmuneTech Inc, H1 2017 Cervical Cancer - Pipeline by Oncobiologics Inc, H1 2017 Cervical Cancer - Pipeline by Oryx GmbH & Co KG, H1 2017 Cervical Cancer - Pipeline by PDS Biotechnology Corp, H1 2017 Cervical Cancer - Pipeline by Pfizer Inc, H1 2017 Cervical Cancer - Pipeline by Pharma Mar SA, H1 2017 Cervical Cancer - Pipeline by Psicofarma SA de CV, H1 2017 Cervical Cancer - Pipeline by Puma Biotechnology Inc, H1 2017 Cervical Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017 Cervical Cancer - Pipeline by Richter Gedeon Nyrt, H1 2017 Cervical Cancer - Pipeline by Samyang Holdings Corp, H1 2017 Cervical Cancer - Pipeline by Sanofi, H1 2017 Cervical Cancer - Pipeline by Seattle Genetics Inc, H1 2017 Cervical Cancer - Pipeline by Selecta Biosciences Inc, H1 2017 Cervical Cancer - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2017 Cervical Cancer - Pipeline by Sirnaomics Inc, H1 2017 Cervical Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 Cervical Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017 Cervical Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H1 2017 Cervical Cancer - Pipeline by Theravectys SA, H1 2017 Cervical Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2017 Cervical Cancer - Pipeline by Tomegavax Inc, H1 2017 Cervical Cancer - Pipeline by UbiVac LLC, H1 2017 Cervical Cancer - Pipeline by VLPbio, H1 2017 Cervical Cancer - Pipeline by Wellstat Biologics Corp, H1 2017 Cervical Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H1 2017 Cervical Cancer - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017 Cervical Cancer - Dormant Projects, H1 2017 Cervical Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017 Cervical Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017 Cervical Cancer - Dormant Projects, H1 2017 (Contd..3), H1 2017 Cervical Cancer - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
